Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)

Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-Cov-2 Infection (COVID-BioVac)

Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)

The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.

Inclusion Criteria:

• Age ≥18 years
• Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others
• Signing of informed consent from January to March 2021

Exclusion Criteria:

• none